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Abstract 
The effects of L-camitine on the pyruvate dehydrogenase (PDH) complex and camitine palmitoyl transferase (CPT) were studied in muscle of 16 
long-distance runners (LDR). These subjects received placebo or L-camitine (2 g orally) during a 4-week period of training. Athletes receiving 
L-carnitine showed a dramatic increase (P c 0.001) in the PDH complex activities. By contrast, the levels of CPT, both 1 and 2, were unchanged. 
No significant changes were observed after placebo administration. We previously reported [Huertas R. et al., Biochem. Biophys. Res. Commun. 
188 (1992) 102-1071 that L-camitine induces an increase in the activities of complexes I, III and IV of the respiratory chain in muscle of LDR. Taken 
together, our data suggest hat the improvement in (maximal oxygen consumption) Voz max observed in LDR after L-camitine administration is based 
on these biochemical findings. 
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1. Introduction 
The energetic demand during endurance xercise relies 
almost exclusively upon the aerobic metabolism of car- 
bohydrates and fatty acids. The pyruvate oxidation rate 
is controlled by pyruvate dehydrogenase complex activ- 
ity. The PDH complex is composed of three catalytic 
enzymes (PDH, lipoamide transacetylase, and lipoamide 
dehydrogenase) and two regulatory enzymes (PDH ki- 
nase and PDH phosphatase) [l]. 
The long-chain fatty acid (LCFA) oxidation rate is 
controlled by CPT activity. CPT has two functional loca- 
tions within the mitochondrion [2]: CPT 1, is located on 
the inner surface of the outer mitochondrial membrane 
and CPT 2 is situated on the inner surface of the inner 
mitochondrial membrane. 
The oxidation of LCFA is almost completely depend- 
ent on carnitine [2]. Moreover, carnitine and carnitine 
acetyl transferase (CAT) are known to control the acetyl 
CoA/CoA ratio and therefore pyruvate oxidation [3]. 
Recently, we documented [4] a marked increase in 
activities of complexes I, III and IV of the respiratory 
chain in muscle of endurance athletes receiving L-car- 
nitine. The aim of the present work is to assess how 
*Corresponding author. Fax: (34) (1) 469 5775. 
endurance exercise modifies PDH and CPT activities in 
long-distance runners with and without carnitine supple- 
mentation. 
2. Materials and methods 
2.1. Experimental protocol 
All the subjects were volunteers and expressed their informed consent 
to participate in the study. Sixteen well-trained male athletes (double 
blind, parallel groups) were studied. All of them were LDR, a speciality 
requiring physical endurance. Age was 28.3 & 7.1 years (mean f S.D.), 
body weight was 67 + 5.1 kg (mean f S.D.). Controls (n = 22) were 
all sedentary age-matched males. Body weight was 69.2 f 6.7 
(mean f SD.). 
Both, controls and athletes, had a dietary regimen of 3,500 to 4,000 
kcal/day, of which proteins represented 13% to 15% of the total caloric 
intake, and lipids 25% to 30%. Muscle needle biopsies (Vastus lateralis, 
average net weight: lwl50 mg) were taken at rest to determine basal 
values of the PDH complex and CPT. The LDR were then divided at 
random in two groups: the first group was treated with 2 g orally of 
L-camitine (Sigma-Tau) for 28 days; the other group received placebo 
during the same period of time. 
Camitine supplementation was suspended 12 h before muscle sam- 
pling. At the same time, the athletes of the two groups started a 4 weeks 
endurance training program. The weekly training program consisted of 
running below the anaerobic threshold, 40% to 50% of the maximal 
oxygen consumption (Vo2 _, for 90 minlday for 5 days, and at the 
anaerobic threshold, 70% to 80% of the Vo2 maX, for 60 min for the other 
2 days, corresponding to 13&140 km per week. At the end of the 
training period, 28 days, a second biopsy was performed (at rest) and 
the PDH complex and CPT activities, were reexamined. All biopsies 
were immediately frozen and stored in liquid nitrogen until analysis, 
which was done at the end of the protocol. 
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2.2. Biochemical assays 
Muscle biopsies were homogenized in 15 volumes of 0.15 M KCl, 50 
mM Tris-HCl pH 7.4 in all-glass homogenizers. CPT was measured in 
total muscle homogenates by the forward reaction (CPT 1) [5], and by 
the backward reaction (CPT 2) [6]. PDH complex activity was deter- 
mined in total muscle homogenates by a radiochemical method as 
described [7]. Non-collagen protein (NCP) was measured by the method 
of Lilienthal et al. [8]. 
2.3. Statistical analysis 
Statistical analysis was performed by one-way analysis of variance 
and Student’s t-test for paired and unpaired comparison. 
3. Results 
3.1. PDH complex activities (Table I) 
Basal levels of the PDH complex in muscle of LDR 
were significantly increased (P < 0.05) compared to age- 
and sex-matched control values. Pretreatment activities 
in athletes receiving L-carnitine or placebo were similar. 
LDR receiving L-carnitine showed a dramatic increase 
(P < 0.001) in the activities of PDH complex after treat- 
ment compared to pretreatment levels. By contrast, in 
LDR receiving placebo, no significant changes were ob- 
served after placebo administration. After treatment, 
LDR receiving L-carnitine had activities markedly higher 
(P < 0.001) than LDR receiving placebo. 
3.2. CPT activities (Table 1) 
Under basal conditions, CPT activities, both 1 and 2, 
in muscle of LDR were markedly increased (P c 0.001 
and P c 0.01, respectively) compared to age- and sex- 
matched control levels. Pretreatment activities in athletes 
receiving L-carnitine or placebo were similar. Both in 
athletes receiving placebo and in those receiving car- 
nitine pretreatment levels did not differ significantly 
from post-treatment levels. 
3.3. Carnitine and citrate synthase activities 
Data on carnitine content and citrate synthase (CS) 
activities in muscle of these LDR have been recently 
reported elsewhere [4], (Table 2). 
Under basal conditions, muscle free and total camitine 
content in muscle of LDR were both markedly increased 
compared to normal controls. No significant differences 
in the pretreatment amounts of total camitine (TC), free 
carnitine (FC), short chain acylcamitine (SCAC) and 
long chain acylcamitine (LCAC) were observed between 
carnitine-treated athletes and placebo-receiving athletes. 
In LDR receiving placebo the levels of both TC and FC 
were significantly lower (P c 0.01) after treatment han 
before treatment, whereas SCAC was unchanged and 
LCAC was significantly increased (P < 0.01). By con- 
trast, TC and FC levels were significantly higher 
(P < 0.01) after treatment han before treatment in LDR 
supplemented with L-camitine. However, SCAC and 
LCAC remained unchanged. In addition, the difference 
between camitine-treated athletes and placebo-receiving 
athletes after treatment was markedly significant 
(P < 0.01) for FC and TC. 
The basal levels of CS in muscle of LDR were mark- 
edly increased compared to normal age- and sex- 
matched control values. CS of LDR receiving L-carnitine 
remained unchanged. No significant changes were ob- 
served after placebo administration in CS activity. 
4. Discussion 
We found that the activities of the PDH complex were 
significantly increased in muscle of long-distance runners 
(Table 1). The reasons for these exercise-induced bio- 
chemical effects are unknown yet. Possible mechanisms 
involved have been reviewed elsewhere [9]. 
Our results show that LDR had a marked increase in 
CPT 1 levels, and a less marked, but very significant, 
increase in CPT 2 activities. These findings suggest hat 
during prolonged exercise both CPT 1 and 2, could play 
a central role in controlling the flux of fatty acids into 
the oxidation pathway on human skeletal muscle. Exer- 
cise-induced increase of CPT 2 activity has been previ- 
ously shown in rat skeletal muscle [lo]. However, to our 
knowledge, this is the first report that demonstrates an 
increase of CPT 1 and 2 in muscle of LDR during endur- 
ance exercise. 
Our data indicate that treatment with L-camitine dra- 
matically increased the activities of PDH complex in 
muscle of LDR. Moreover, oral carnitine supplementa- 
tion is able to ‘stabilize’ muscle camitine pool. By con- 
trast, the activities of CPT remained at pretreatment 
levels. The catalytic efficiency of PDH complex is regu- 
lated by a phosphorylationAephosphorylation mecha- 
nism of the a-subunit [ll]. PDH kinase, the inhibiting 
and phosphorylating compound is stimulated by a high 
acetyl-CoAlCoA ratio. During endurance exercise, py- 
Table 1 
PDH complex, and CPT (CPTl and CPT2) activities in muscle of 
endurance athletes 
n PDH complex CPTl CPT2 
Controls 22 2.60 f 0.80 0.28 + 0.051 13.5 & 3.5 
Long distance runners 16 3.82 f 0.94* 1.45 _+ 0.19’ 21.7 + 4.7+ 
Placebo 8 
Before treatment 3.90 rt: 0.96 1.48 f 0.20 22.1 * 4.8 
After treatment 3.88 f 0.98 1.47 f 0.22 22.0 f 4.7 
L-Camitine 8 
Before treatment 3.74 + 0.92 1.42 f 0.18 21.3 + 4.6 
After treatment 6.96 f 1.02** 1.43 + 0.17 21.7 !I 4.8 
Activities are expressed in nmol of substrate utilized’min-’ .mg NCP-’ 
(mean f SD.). *Significant differences vs. controls (P < 0.05); un- 
paired t-test. ‘Significant differences vs. controls (P < 0.001); unpaired 
t-test. “Significant differences vs. controls (P < 0.01); unpaired t-test. 
**Significant differences vs. both pretreatment levels and receiving pla- 
cebo post-treatment levels (P < 0.001; one-way variance analysis). 
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Table 2 
FC, SCAC, LCAC, TC and CS in muscle of endurance athletes 
n FC SCAC LCAC TC CS 
Controls 30 19.3 f 0.8 2.86 + 1.50 0.40 f 0.05 22 f 1.10 120 f 38.5 
Long distance runners 14 21.5 f 3.3* 2.15 f 0.70 0.36 f 0.075 30.7 f 3.7* 309.8 f 68.1* 
Placebo 7 
Before treatment 21.3 f 3.1 2.71 f 0.71 0.34 + 0.07 30.4 f 3.5 307.3 + 68.2 
Aftertreatment 24.1 f 3.2’ 2.76 f 0.80 0.48 + 0.09’ 27.3 f 3.7’ 304.9 f 67.9 
I.-Camitine 7 
Before treatment 27.8 f 3.5 2.8 f 0.7 0.38 f 0.08 30.98 + 3.8 312.3 f 73.2 
After treatment 31.7 f 2.9r 2.7 f 0.8 0.31 ? 0.09 34.8 f 3.4§ 299.8 f 66.5’ 
Carnitines: Values are expressed inprnol. g-’ of noncollagenous protein (mean f S.D.). *Signilicant differences vs. controls (P < 0.01; unpaired t-test). 
Significant differences vs. pretreatment levels (P < 0.01; paired t-test). %ignificant differences vs. both pretreatment and posttreatment receiving 
placebo levels (P < 0.01; one-way variance analysis). 
Citrate synthase: Activities are expressed in nmol of substrate utilized. min-’ . mg NCP-’ (mean f S.D.). *Significant differences vs. controls 
(P < 0.01); unpaired t-test. ‘Significant differences vs. both pretreatment levels and receiving placebo posttreatment levels (P < 0.001; one-way 
variance analysis). 
ruvate is oxidized at high rates. As the production rate 
of acetyl-CoA becomes higher than the rate of its utiliza- 
tion through the Krebs cycle, acetyl-CoA accumulates in 
mitochondria. CAT, together with L-carnitine, provide 
a clearance mechanism by transforming the excess of 
acetyl-CoA into acetylcarnitine. A larger carnitine avail- 
ability in muscle, therefore, can stimulate PDH complex 
activity by forming larger amounts of acetylcarnitine 
from pyruvate-derived acetyl-CoA. In agreement with 
our results, Uziel et al. [7] in an ‘in vitro’ study on iso- 
lated human muscle mitochondria, reported that at py- 
ruvate concentrations above 0.25 mM, only camitine 
concentrations greater than 0.1 mM stimulate PDH 
complex activity. 
Endurance athletes upon L-camitine loading increase 
the values of VoZ ,__, which may be of practical impor- 
tance in improving tolerance during exercise [121. Several 
lines of evidence, at the biochemical evel, seem to sup- 
port such a physiological response; first, L-camitine in- 
duces an increase of the respiratory chain enzyme activ- 
ities in muscle [4]; second, L-camitine stimulates PDH 
complex activity in muscle; and third, L-camitine loading 
prevents the accumulation of LCFA [ 131, which are po- 
tentially deleterious inhibitors of adenylate translocase 
in muscle. However, we can not rule out the possibility 
that L-camitine treatment may affect further factors, i.e. 
B-oxidation enzymes. 
We conclude that in muscle from endurance athletes, 
when pyruvate is oxidized at high rates, L-camitine and 
CAT are able to regulate PDH activity by maintaining 
a favorable acetyl-CoA/CoA ratio. This conclusion is 
consistent with our data previously reported [13], which 
showed that in LDR L-carnitine treatment increased the 
concentration of acetyl-camitine in plasma and its excre- 
tion in the urine. 
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